A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis

Jeske van Pamelen, Chaja M. J. van Ansenwoude, Maria Miguélez Sánchez, Lotte Spijkerbosch, Carla Rodriguez-Mogeda, Lynn van Olst, Susanne M. A. van der Pol, Maarten L. Boon, Marleen J. A. Koel-Simmelink, Tom van Seeters, Birgit I. Lissenberg-Witte, Janet de Beukelaar, Jiske Fermont, Stephan T. F. M. Frequin, Oliver H. H. Gerlach, Guy Laureys, Bob W. van Oosten, Judith van Vliet, Joep Killestein, Charlotte E. Teunissen, Andries E. Budding, Helga E. de Vries, Leo H. Visser

Open source

DOI: 10.3389/fimmu.2026.1955097
Published: 2026-10-19
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1955097,
  title = {A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis},
  author = {Jeske van Pamelen and Chaja M. J. van Ansenwoude and Maria Miguélez Sánchez and Lotte Spijkerbosch and Carla Rodriguez-Mogeda and Lynn van Olst and Susanne M. A. van der Pol and Maarten L. Boon and Marleen J. A. Koel-Simmelink and Tom van Seeters and Birgit I. Lissenberg-Witte and Janet de Beukelaar and Jiske Fermont and Stephan T. F. M. Frequin and Oliver H. H. Gerlach and Guy Laureys and Bob W. van Oosten and Judith van Vliet and Joep Killestein and Charlotte E. Teunissen and Andries E. Budding and Helga E. de Vries and Leo H. Visser},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1955097},
  url = {https://doi.org/10.3389/fimmu.2026.1955097}
}

RIS

TY  - JOUR
TI  - A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis
AU  - Jeske van Pamelen
AU  - Chaja M. J. van Ansenwoude
AU  - Maria Miguélez Sánchez
AU  - Lotte Spijkerbosch
AU  - Carla Rodriguez-Mogeda
AU  - Lynn van Olst
AU  - Susanne M. A. van der Pol
AU  - Maarten L. Boon
AU  - Marleen J. A. Koel-Simmelink
AU  - Tom van Seeters
AU  - Birgit I. Lissenberg-Witte
AU  - Janet de Beukelaar
AU  - Jiske Fermont
AU  - Stephan T. F. M. Frequin
AU  - Oliver H. H. Gerlach
AU  - Guy Laureys
AU  - Bob W. van Oosten
AU  - Judith van Vliet
AU  - Joep Killestein
AU  - Charlotte E. Teunissen
AU  - Andries E. Budding
AU  - Helga E. de Vries
AU  - Leo H. Visser
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1955097
UR  - https://doi.org/10.3389/fimmu.2026.1955097
ER  -

APA

Pamelen, J. V., Ansenwoude, C. M. J. V., Sánchez, M. M., Spijkerbosch, L., Rodriguez-Mogeda, C., Olst, L. V., Pol, S. M. A. V. D., Boon, M. L., Koel-Simmelink, M. J. A., Seeters, T. V., Lissenberg-Witte, B. I., Beukelaar, J. D., Fermont, J., Frequin, S. T. F. M., Gerlach, O. H. H., Laureys, G., Oosten, B. W. V., Vliet, J. V., Killestein, J., Teunissen, C. E., Budding, A. E., Vries, H. E. D., & Visser, L. H. (2026). A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1955097

Source records

crossref · retrieved 2026-11-08T13:12:31.871Z